RxDoctor Payments DataLook up a doctor →

William Lee, MD

Cornea and External Diseases Specialist · Atlanta, GANPI 1366406787

Payments from drug & device makers

$545,245in general payments, 2019–2025

Across 1,030 payments — averaging $529.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$148K
  • Sun Pharmaceutical Industries Inc.$109K
  • Oyster Point Pharma, Inc.$75K
  • Glaukos Corporation$43K
  • Dompe US, Inc.$42K
  • Eyevance Pharmaceuticals LLC$38K
  • plus $91K from 30 others

What the payments were for

  • Consulting fees$67,56313%
  • Speaking & faculty fees$352,62070%
  • Travel & lodging$49,25010%
  • Food & beverage$31,8946%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cornea and external diseases specialist providers in Georgiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$474,722
Medicare patients
995
Services billed
2,636

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj31$1,220,858
RestasisCyclosporine112$117,082
XiidraLifitegrast69$78,011
Prednisolone Acetate943$38,790
CequaCyclosporine42$26,532
MieboPerfluorohexyloctane/Pf28$22,632
Cyclosporine32$19,628
LumiganBimatoprost31$18,114
ProlensaBromfenac Sodium51$17,850
CombiganBrimonidine Tartrate/Timolol46$12,317
TyrvayaVarenicline Tartrate16$11,776
Difluprednate91$8,391
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol59$8,248
Loteprednol Etabonate56$7,683
Alphagan PBrimonidine Tartrate18$7,570

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$41,638$1,220,85831 claims
AbbVieRestasis, Lumigan, Combigan, Alphagan P$2,170$155,083207 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Zirgan$148,049$105,718108 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Lotemax Sm$358$31,055129 claims
Sun Pharmaceutical Industries Inc.Cequa$108,693$26,53242 claims
Oyster Point Pharma, Inc.Tyrvaya$75,390$11,77616 claims
Kala Pharmaceuticals, Inc.Inveltys$12,917$5,02417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cornea and external diseases specialist providers in Georgiaon file to place this against a meaningful peer group, so we don't.

Other cornea and external diseases specialist in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →